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ABSTRACT 
A hairless mouse-herpes simplex virus system was used to evaluate the efficacy of a 
variety of antiviral compounds, inducers of interferon (IF) and exogenous IF. In this model 
herpes simplex virus produces a local lesion which can be readily examined . Of the DNA 
virus inhibitors studied, 9-{J-D-arabinofuranosyladenine delayed the onset and reduced the 
incidence and severity of cutaneous herpetic lesions. Topical application of kethoxal cream 
(3-ethoxy-2-oxobutyraldehyde hydrate) produced a marked suppression of the skin lesions. 
Cytosine arabinoside was inactive. Of the inducers of IF tested, polyriboinosinic: polyribo-
cytidylic acid and tilorone hydrochloride (2, 7 -his [2-( diethylamino)ethoxy )-lluoren-9-one di-
hydrochloride) did not prevent lesion !ormation. Exogenous IF was also without effect. 
A number of reports have described the experi-
mental production of skin lesions by herpes sim-
plex virus in mice [1], rats [2], and more recently 
in hairless mice [3-5]. Unlike most herpetic le-
sions in man, those in hairless mice progress from 
a small localized lesion to a spread of virus along 
peripheral nerves [5], producing what has been 
described by others [4, 5] as a zosteriform-like 
lesion which becomes necrotic. Frequently, neuro-
logic involvement results in death. Underwood [3] 
used hairless mice to evaluate a viricidal sub-
stance, kethoxal (3-ethoxy-2-oxobutyraldehyde 
hydrate), for its potency as a topical antiherpetic 
compound. In the present study a hairless mouse-
herpes simplex model was employed to evaluate 
the efficacy of a variety of antiviral agents, 
including inducers of interferon (IF) and exoge-
nous IF. 
MATERIALS AND METHODS 
Virus. The S strain of herpes simplex virus, originally 
isolated from a facial skin lesion, was obtained after 
multiple passages in HEp-2 cells from Dr. Irwin Schultz, 
Washington University School of Medicine , St. Louis. 
Missouri. The virus was propagated in HEp-2 cells and 
contained 1.8 x 106 plaque-forming units (PFU)/ml 
when assayed on HEp-2 monolayers. The virus pool was 
stored at -60° C. Preliminary studies demonstrated 
that this strain was 10-fold less sensitive to the action of 
IF than vesicular stomatitis virus (Indiana strain) on 
L-929 monolayers. 
Mice. Hairless mice were obtained from Dr. A. Fried-
man-Kien, New York University School of Medicine, 
New York. The mice, weighing 15-20 gm, were random 
bred and were derived .from the HRS/J strain of The 
Jackson Laboratory, Bar Harbor, Maine. Preliminary 
tests demonstrated that this strain of mice was capable 
of producing IF to approximately the same extent as 
random-bred Swiss mice following dosage with two 
inducers of interferon, polyribinosinic: polyribocytidylic 
acid (poly I: C) or tilorone hydrochloride (2, 7-bis [2-
(diethylamine) ethoxy ]-fluorene-9-one dihydrochloride). 
Method of infection. Mice were anaesthetized by 
ether and the lumbar area was scratched six times with a 
0.25-in. 27 gauge needle in a cross-hatched pattern. A 
cotton swab saturated with virus diluted in iced distilled 
water was rubbed over the abraded area for approxi-
mately 10 sec. The dilution of virus administered 
routinely was 10-fold more concentrated than the dilu-
tion which produced skin lesions in 50 percent of the 
animals. A lesion 10-19 mm in length (score of 2.0, see 
below) was termed severe. Under the conditions em-
ployed throughout these studies an incidence of infec-
tion resulting in a lesion score of 2.0 or greater was 
approximately 90 percent by day 6-8. 
Skin lesions. Initially, skin lesions usually appeared in 
the control mice as early as the fourth day after 
inoculation as several small punctate lesions or as a 
single lesion less than 5 mm in length. In general, by 5-6 
days the cutaneous lesion enlarged as a unilateral band 
which progressed downward from the site of inoculation 
to reach the midline of the abdomen by 6-8 days 
postinoculation. Frequently, when the original site of 
inoculation was on the midline of the spine, a bilateral 
band almost completely encircled the mouse. Often the 
appearance of a broad "bleached" band of skin preceded 
the dermal lesion. After the sixth day postinoculation, 
approximately half of the control mice with cutaneous 
lesions showed signs of neurologic involvement and 
paralysis which resulted in death. From the tenth day 
onward, surviving controls presented a dried, regressing 
and healing lesion. To evaluate the progression of the 
epidermal lesion, it was measured at daily intervals for 
14 days and the lesion was scored 0 to 4: 0 = no lesion; 
0.5 = several discrete punctate lesions or a lesion less 
than 5 mm in length; 1.0 = lesion 5-9 mm; 2.0 = lesion 
10-19 mm; 3.0 = lesion 20-29 mm: and 4.0 = lesion over 
30 mm in length. When the lesion was bilateral, the 
longer epidermal band was scored. Others have de-
. scribed the production of lesions in hairless mice with 
various strains of herpes simplex [3-5]. 
Compounds. Of the DNA virus inhibitors studied, 
9-{:1-D-arabinofuranosyladenine (ara-A) was purchased 
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Tilorone hydrochloride, 2, 7-bis[2-(diethylamino) 
ethoxy]-fluoren-9-one dihydrochloride, an inducer of IF, 
was obtained through the generosity of Dr. G. Mayer of 
The Merrell National Laboratories, Cincinnati, Ohio. 
Another inducer of IF, polyriboinosinic: polyribocyti-
dylic acid, lot No. 11-8-321, was purchased from Miles 
Laboratories, Ekhart, Indiana. 
For treatment, ara-A (125 mg/kg) was injected intra-
dermally (ID) at the site 15 min prior to virus inoculation, 
4 hr post-inoculation, and twice daily (6 hr apart) during 
the 14-day experimental period . The methyl cellulose 
(MC) vehicle was given at the same dosage schedule and 
served as control. Previous tests showed that MC did not 
inhibit lesion formation . A dose of 12.5 mg/kg of ara-C 
was injected ID 15 min pre-inoculation and once daily 
for a total of 8 doses. Tilorone was given orally at 250 
mg/kg once daily one day before inoculation, 2 hr 
pre-inoculation, and once daily for 6 additional days. 
Poly I: C, 5 mg/kg, was injected ID or intraperitoneally 
(IP) 3 hr prior to inoculation and once every 2 days 
thereafter for 6 doses. Kethoxal cream (5 %) or cream 
base as a control was applied topically 2 and 4 hr post-
inoculation in 50-100 mg doses. In preliminary tests 
lower dose levels of the test compounds were not 
effective . A dose of ara-A greater than 125 mg/kg was not 
administered because of the accumulation of an insolu-
ble drug mass at the site of injection. Higher daily doses 
of ara-C or tilorone were not given to avoid possible toxic 
effects. For ID or IP treatment the drugs were adminis-
tered in a 0.1-ml volume . All ID injections were given 
under ether anaesthesia . The dosages and the treatment 
schedules were selected because they had previously 
been reported active in a number of other in vivo 
systems [3, 6-9]. 
Preparation of exogenous IF. The mouse serum IF was 
prepared in haired mice (random-bred Swiss mice) by 
intravenous injection of Newcastle disease virus ir-
radiated with ultraviolet light, as previously described 
[10 ]. Subcutaneous injection of the equivalent of 2000 
international units (IU) of IF was given (0.1 ml) at the 
site of infection 15 min prior to inoculation, 4 hr 
post-inoculation, and then twice daily 6 hr apart for 9 
days. 
RESULTS 
Effect of inhibitors of DNA viruses, inducers of 
IF or exogenous IF. The effect of various antiviral 
agents on the incidence of cutaneous herpes sim-
plex lesions in hairless mice is presented in the 
Table. Similar results were ' obtained in five other 
trials. The numerator of the fraction represents 
the number of mice exhibiting lesion scores of 2.0 
or greater . The denominator indicates the number 
of surviving animals. Mice that died were ex-
cluded from the calculations. It can be seen that 
80-100 percent of the controls (MC- or cream base-
treated) had epidermal lesion scores of 2.0 or 
greater 6-8 days post-inoculation. The infection 
produced a fatal neurologic disease in approxi-
mately half of the control mice. However, in the 
latter part of the 14-day experimental period, 
certain of the surviving MC control mice showed 
spontaneous regression of the dermal lesions. 
Ara-A at dosages of 125 mg/kg delayed the onset 
and reduced the incidence of lesion production 
and, as shown below, inhibited the severity of the 
lesions. Ara-A protected all infected mice from 
fatal infection. Ara-C and tilorone had no inhibi-
tory effect on lesion development. Although poly 
I: C given ID or IP did not prevent lesion forma-
tion, the few surviving mice appeared to heal more 
rapidly than the control mice. However, this 
observation was not noted in every experiment. 
Topical application of kethoxal cream produced a 
marked suppression of cutaneous lesions and all 
infected mice survived. In an experiment not 
shown in the Table, subcutaneous administration 
of a total of 36,000 IU of IF/mouse injected at the 
site of infection over 9 days failed to retard lesion 
development. 
Effect of drug treatment on the rate of lesion 
development. The results in the Table show the 
incidence of lesions but do not take into account 
the progression of lesion size. The effect of the 
antiviral agents on the development of the cutane-
ous lesions is shown in the Figure. These data were 
derived from the experiment summarized in the 
Table but illustrate the effect of chemotherapy on 
lesion size. The lesion score here is an average of 
the lesion size of surviving animals. In the MC- or 
cream base-treated controls, the peak of lesion 
formation was noted approximately 8 days post-
inoculation. Most of the control mice displayed 
skin lesions of 30 mm or greater in length which 
extended from the spine to the midline of the 
abdomen. By day 14 spontaneous healing oc-
curred in some of the MC control mice, as 
indicated by a lower lesion score. Ara-A treatment 
reduced the lesion score by approximately 40-45 
percent at the peak of lesion development and 
subsequently by 50-55 percent at 10-14 days . In 
numerous experiments kethoxal, a viricidal sub-
stance, prevented lesion formation in most mice 
and in this trial it protected all mice. In several 
experiments, including this one, there was a 
suggestion that poly I: C may have accelerated the 
healing process, but poly I: C did not have a 
significant influence on the initial development of 
lesions. The 85-95 percent and 80-85 percent 
calculated reduction is based on only 4 and 2 
surviving mice, respectively. However, this ob-
servation was not noted in every experiment. Ara-
C and tilorone were inactive in this test system. 
DISCUSSION 
In this study the protective action of several 
inhibitors of DNA-containing viruses and in-
ducers of IF and exogenous IF was evaluated in a 
cutaneous herpes simplex infection in hairless 
mice. The dose regimens for the various antiviral 
agents had been previously reported active in a 
number of other in vivo models [3, 6-9) . 
Ara-A, given at the time of inoculation and 
continued through the experimental period of 14 
days, was capable of markedly improving the 
course of infection. This effect is in agreement 
with earlier reports of the antiviral activity of 
ara-A against herpes simplex in hamsters [11-13], 
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TABLE 
Effect of antiviral agents on the incidence of herpetic lesions with a score of 2.0" or greater 
Mice with lesion score of 2.0 or greater/survivors 
Drug Dose' Route 
Control (MC)• 0.1 ml ID• 
Control (MC) 0.1 ml IP 
Control cream - Topical 
Ara-A 125 mg/kg ID 
Ara-C 12.5 mg/kg ID 
Poly I:C 5 mg/kg ID 
Poly l:C 5 mg/kg IP 
Tilorone 250 mg/kg PO 
Kethoxal cream 250 mg/kg Topical 
• Score of 2.0 = lesion 10-19 mm in length. 
"See text for therapeutic regimen. 
c Num her of survivors/total number infected. 











• ID = intradermal, IP = intraperitoneal, PO = per os. 
haired mice [9, 11], rabbits and monkeys [14] . 
Kethoxal was applied several hours follo\Ving 
virus inoculation and consistently prevented le-
sion development. This observation confirms the 
antiherpetic activity of kethoxal when applied 
topically in hairless mice and baby rabbits [3]. 
Since the mode of action of kethoxal is attributed 
to viricidal activity [15], it can be assumed that 
kethoxal destroyed virus infectivity thereby pre-
venting the initiation of infection. Ara-C has been 
reported active against herpes simplex keratitis in 
hamsters [16], rabbits [14, 17-19). monkeys [17] 
and herpes simplex infections in man which 
included one case of generalized cutaneous herpes 
simplex [20-22 and Chow A, Fiala M, Hyrniuk W, 
et al, unpublished data]. Ara-C therapy produced 
a beneficial effect in three infants with congenital 
cytomegalic inclusion disease [23]. Other studies 
show that ara-C is substantially inactive in the 
course of congenital cytomegalic inclusion disease 
[McCracken GH Jr, Luby JP, unpublished data] 
and does not reduce mortality, although it delayed 
and/or partially suppressed viral replication in 
certain tissues of suckling mice infected with 
Herpesvirus hominis [Kern ER, Overall JC, Glas-
gow LA, unpublished data]. In the present study 
ara-C neither inhibited lesion development nor 
prevented fatal neurologic sequelae. 
The finding that exogenous IF, as well as the IF 
inducers, poly I: C and tilorone, had no consistent 
beneficial effect is in agreement with previous 
Ieports on the relative resistance of certain strains 
of herpes simplex to IF. Oh has recently reported 
that type 1 strains of Herpesvirus hominis are 
resistant to the action of poly I: C in vitro [24]. 
The virus strain employed in the present study 
was found relatively insensitive to IF and this may 
explain its lack of response to IF and IF inducers. 
Studies with strains of herpes simplex sensitive to 
the action of IF may provide further information 
on day indicated 
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FIG. Effect of antiviral agents on progression of lesion 
development. The skin of hairless mice was scratched 
and herpes simplex virus strain S was rubbed on the 
abraded area. Ara-A and ara-C were injected intrader-
mally (ID), as described in Materials and Methods . Poly 
I:C was given ID or intraperitoneally (IP). Tilorone was 
administered orally and kethoxal cream or the control 
base was applied topically. Methyl cellulose (MC) 
was injected ID or IP. The lesion score is an average of 
the lesion size in surviving animals. 
on the efficacy of exogenous IF and inducers of IF 
on cutaneous herpetic lesions. Poly I: C may have 
accelerated the healing process of the lesions and 
this observation is not completely understood. 
However, it is now recognized that inducers of IF 
stimulate a multiplicity of host defense responses 
in addition to the induction of circulating IF [25]. 
Kethoxal protected in this model, but the 
efficacy observed resulted from topical applica-
tion of the viricidal agent shortly after infection. 
With respect to this observation, it is noteworthy 
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that Underwood and Nichol [26] recently reported 
that kethoxal was not effective in a clinical 
double-blind study when applied topically at the 
appearance of the first symptoms of a cold sore in 
man. The lack of clinical efficacy was attributed 
to the presence of high levels of herpes virus in the 
skin prior to the time when the initial symptoms 
were noted. 
In spite of the continued difficulty in treating 
cutaneous herpes simplex infection in man, this 
study indicates that in mice lesions can be limited 
with parenterally administered ara-A and it pro-
vides further evidence that similar modes of 
chemotherapy may eventually prove useful in 
treating cutaneous herpetic infections. 
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